BioCryst Pharmaceuticals (BCRX), which sells flu drugs and develops ORLADEYO to treat hereditary angioedema, rose sharply on unaudited revenue data published. So, on January 10, the stock price jumped almost 28%, and the trading session was closed at $ 14.79 with a market capitalization of $ 2.659 billion. According to the chart, before the ascent, the worth had been dropping for 5 days and reached $ 11.56. Recall that the only drug of the company ORLADEYO was approved more than a year ago and since its launch has been in high demand among patients and doctors, as evidenced by data on preliminary results for fiscal 2021 and Q4.
BioCryst today announced preliminary financial results that put ORLADEYO at more than $ 45 million in revenues for the last quarter, while at $ 122 million in annual revenues. Given the demand, efficacy, and growing adherents for the drug, the company expects at least $ 250 million in net revenues in 2022. In addition, sales could exceed $ 1 billion. However, do not forget that the actual financial results may differ significantly from the figures indicated above. In order not to be at risk, we kindly request you to study further this company and its achievements.